An overview of Mesenchymal stem cell therapy in COVID-19 patients (Review)

An infection causes coronavirus disease (COVID-19) with a virus from the coronavirus family known as SARS coronavirus. By entering the coronal protein into the host's angiotensin-4 receptor, the virus affects lung cells and other organs, including the heart and immune system. While there is currently no particular treatment for COVID-19 disease, Mesenchymal stromal cells (MSCs) have been proposed as a potential therapy to treat drug-resistant lung infections.

In this article, the keywords Mesenchymal stromal cells, stem cells, and COVID-19 were searched in the titles and abstracts of articles published in reputable international scientific databases. After several stages of removing duplicate and unrelated items, 39 articles were finally used. MSCs, due to their unique properties, including immune system regulation and tissue regeneration capabilities, significantly affect the treatment of COVID-19. Also, in this regard, several studies have obtained permission to reach the clinical phase and are currently being investigated. There is a pressing need for extensive research to evaluate the efficacy and safety profile of MSCs therapy in COVID-19 patients.